James Sandy is an accomplished Development Consultant at LEVICEPT LTD since June 2025, focusing on the phase 3 development plan for a lead asset in treating osteoarthritis. Previously, James held the position of Chief Development Officer at F-star Therapeutics from March 2022 to August 2025 and at Ellipses Pharma from April 2019 to March 2022, where responsibilities included strategizing and managing oncology clinical trials and drug development functions. James also served as Chief Development Officer at Immunocore Limited from December 2015 to March 2019, overseeing the delivery of immune oncology programs, and at Creabilis Ltd from July 2011 to December 2015, establishing the development operations. Prior experience includes project guidance roles at The Canterbury Consulting Group and key leadership positions at Pfizer Global R&D, where James managed development operations across Europe and Asia. James holds an MPhil in Statistics/Outcomes Research from Imperial College London.
This person is not in the org chart
This person is not in any teams
This person is not in any offices